Albert Hofmann synthesized lysergic acid diethylamide on November 16, 1938. He was looking for a respiratory stimulant. He found something else. He set the compound aside for five years because the lab animals showed no interesting response.
On April 16, 1943, he went back to it. During the re-synthesis, a small amount absorbed through his fingertips. He went home early, feeling odd, and experienced “a remarkable restlessness, combined with a slight dizziness.” He closed his eyes and saw “an uninterrupted stream of fantastic pictures, extraordinary shapes with intense, kaleidoscopic play of colors.” The world’s first acid trip lasted two hours. It was accidental.
Three days later, on April 19, he took 250 micrograms intentionally. This was, he later admitted, a significant overestimate of the active dose. He rode his bicycle home from the Sandoz laboratory in Basel as the full effects hit. April 19 is now known as “Bicycle Day” in psychedelic culture. Hofmann spent the ride convinced he was dying, that his neighbor was a witch, and that the furniture in his house was threatening him. The next morning, he felt fine. Better than fine. He walked outside and the world looked, he said, “as if newly created.”
He was 37. He lived to 102. He spent the remaining 65 years arguing about what he’d found.
How He’d Argue
Hofmann argued the way a Swiss chemist argues: precisely, calmly, with data, and with the quiet frustration of a man who’d watched his discovery hijacked by people who didn’t understand it.
He’d start with the chemistry. LSD-25 is an ergot alkaloid derivative. Ergot is a fungus that grows on rye. It has been implicated in the Salem witch trials, in medieval episodes of mass hallucination called “St. Anthony’s fire,” and in the Eleusinian Mysteries of ancient Greece, where a psychoactive drink called kykeon may have contained ergot compounds. Hofmann believed he’d found the chemical key to a door that humanity had been trying to open for millennia.
Then you’d mention the 1960s. Timothy Leary. Ken Kesey. The Summer of Love. The recreational use that turned LSD from a promising psychiatric tool into a Schedule I controlled substance in 1970.
And the calm Swiss chemist would tighten. Not with anger. With sorrow. He called LSD his “problem child.” He believed, until the day he died, that LSD was one of the most important pharmacological discoveries in history — a tool for psychiatric research, for treating addiction and depression, for understanding consciousness itself — and that its prohibition was a scientific tragedy caused by irresponsible use.
“I was visited by the spirit of a new substance,” he told an interviewer. He didn’t mean this metaphorically. Hofmann was a deeply spiritual man who believed that chemistry was a doorway to mystical experience, not a replacement for it. He took LSD himself, periodically, in controlled settings, for decades. He reported that it deepened his connection to nature, clarified his thinking, and produced insights he could not have reached through normal cognition.
What He’d Fight About
The argument was always the same: LSD is a medicine, not a drug. The distinction mattered to Hofmann with an intensity that surprised people who expected the inventor of acid to be a hippie.
He was not a hippie. He was a Sandoz Pharmaceuticals research chemist who wore a suit to work, published in peer-reviewed journals, and believed that psychedelic experience required structure, intention, and clinical supervision. He supported Stanislav Grof’s LSD psychotherapy research. He supported the treatment of terminal cancer patients with psilocybin. He advocated, consistently and persistently, for the controlled reintroduction of psychedelics into psychiatric practice.
He lived to see the beginning of that reintroduction. In the 2000s, Johns Hopkins, NYU, and Imperial College London began clinical trials of psilocybin for depression, addiction, and end-of-life anxiety. The results supported everything Hofmann had been arguing since 1943. He was gratified. He was also 100 years old by the time the research began, which meant the argument had taken six decades to reach its first preliminary vindication.
“I think that in human evolution it has never been as necessary to have this substance,” he said at a 2006 symposium celebrating his 100th birthday. He was frail, sharp-eyed, and completely certain. The audience gave him a standing ovation. It was the only standing ovation a Swiss research chemist has ever received at a psychedelics conference, and he accepted it the way he’d accepted the original discovery: with gratitude, wonder, and the persistent suspicion that people still didn’t fully understand what he’d found.
The chemist who accidentally discovered LSD spent 65 years arguing it was medicine. The argument outlasted the prohibition, and the science is finally catching up.
Talk to Albert Hofmann — he’ll explain the chemistry first. Then the mystery. He never saw a difference between them.